Avalon Pharma signs agreement to commercialize Dupilumab biosimilar
- Source
- Argaam - Company Disclosures
- Source link
- https://www.argaam.com/en/article/articledetail/id/1930183
- Published
- 2026-08-18 10:20:00
- Discovered by ProcIntel
- 2026-08-18 15:16:26
- Category
- Supplier Risk
- Geography
- Saudi Arabia, UAE
- Organisations
- —
- Review status
- Pending
- Record type
- REAL
Summary
<p><img src="https://argaamplus.s3.amazonaws.com/ce6cd0fc-562a-4bc7-bb47-9a988b13a218.png" ></p> <p class="ckeCaption" >The agreement grants Avalon Pharma exclusive registration and commercialization rights for Dupilumab in Saudi Arabia and MENA.</p> <hr> <p >Middle East Pharmaceutical Industries Co. (<a href="https://www.argaam.com/en/tadawul/tasi/avalon-pharma" target="_blank">Avalon Pharma</a>)signed on Aug. 17 a strategic commercialization agreement with Bio-Thera Solutions, obtaining exclusive rights to register and commercialize Dupilumab, a Dupixent biosimilar, in Saudi Arabia and the MENA region.</p> <p ></p> <div >The agreement has a renewable 15-year term, Avalon Pharma said in a statement to <strong>Tadawul</strong>. The contract value represents less than 5% of the company’s total revenue, based on its annual financial statements for 2025.</div> <div ></div> <div >The agreement grants Avalon Pharma additional rights to localize the product’s manufacturing in the future.</div> <div ></div> <div >Avalon said the financial impact is expected to be reflected in its results from the product’s launch in 2031, provided there are no pending patents. The company expects the contract to generate cumulative revenue of no less than SAR 400 million during the first seven years of the contract term.</div> <div ></div> <div >The partnership strengthens Avalon Pharma’s portfolio of specialized biologic and immunology medicines, the company said, adding that there are no related parties.</div>
Procurement Relevance Gate
- geographic_exposure (weight 8) — matched on "2 linked geographies"
Initial Signal Assessment ProcIntel's automatic, provisional read of this individual Signal -- Initial Significance and Initial Confidence, computed deterministically before any Event extraction or human review.
A provisional, automatically-computed reading of this individual Signal, before Event extraction or human review. Not a final rating.
Not Assessed — this Signal did not pass the Procurement Relevance Gate, or is fictional/excluded test data.